Phio Pharmaceuticals Corp.

NasdaqCM:PHIO Stock Report

Market Cap: US$6.4m

Phio Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:PHIO Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
07 Jun 24BuyUS$740Robert BittermanIndividual111.11US$6.66
06 Jun 24BuyUS$750Robert BittermanIndividual111.11US$6.75

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of PHIO?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders3,6470.0763%
Institutions886,27318.6%
General Public3,886,92881.4%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 1659.5%.

Top Shareholders

Top 23 shareholders own 18.63% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.8%
Orca Capital GmbH, Asset Management Arm
514,965US$690.1k0%29.7%
2.52%
Intracoastal Capital LLC
120,436US$161.4k0%1.62%
1.9%
Heights Capital Management, Inc.
90,988US$121.9k4,190%0.04%
0.93%
Citadel Advisors LLC
44,526US$59.7k0%no data
0.89%
Hudson River Trading LLC, Asset Management Arm
42,338US$56.7k0%no data
0.86%
Virtu Financial LLC, Asset Management Arm
40,910US$54.8k0%no data
0.27%
Cetera Investment Advisers LLC
13,000US$17.4k0%no data
0.12%
Morgan Stanley, Investment Banking and Brokerage Investments
5,911US$7.9k0%no data
0.098%
Tower Research Capital Europe Limited
4,682US$6.3k299%no data
0.065%
Geode Capital Management, LLC
3,126US$4.2k0%no data
0.057%
The Vanguard Group, Inc.
2,708US$3.6k0%no data
0.05%
UBS Asset Management AG
2,397US$3.2k42.3%no data
0.031%
Robert Bitterman
1,499US$2.0k-12.9%no data
0.013%
Caitlin Kontulis
639US$856.50%no data
0.0093%
Robert Ferrara
445US$596.60%no data
0.0075%
Curtis Lockshin
356US$476.90%no data
0.0075%
Jonathan Freeman
356US$476.90%no data
0.0074%
Patricia Bradford
352US$471.80%no data
0.0043%
Barclays Bank PLC, Securities Investments
203US$272.00%no data
0.0013%
SBI Holdings Inc., Asset Management Arm
63US$84.50%no data
0.00019%
Activest Wealth Management, LLC
9US$12.20%no data
0.00015%
Bank of America Corporation, Asset Management Arm
7US$9.60%no data
0.00008%
Blackstone Alternative Investment Advisors LLC
4US$5.10%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/07 10:22
End of Day Share Price 2025/03/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Phio Pharmaceuticals Corp. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Maxim JacobsEdison Investment Research
Mark BreidenbachH.C. Wainwright & Co.
Vernon BernardinoH.C. Wainwright & Co.